immune (dys-)regulation & immunomodulation in liver disease

The Triantafyllou Lab investigates the microbial, metabolic, molecular and cellular crosstalk that underlies immune dysregulation during acute and chronic liver injury. To determine this, we study both human tissue samples and in vivo disease models and employ flow cytometry, intravital imaging, single-cell and spatial multi-omics. Throughout our work, we seek to advance our immunological understanding of liver disease pathogenesis and identify targets for developing immunomodulatory therapeutic approaches.

One part of our research focuses on the dysregulated, and often ineffective, immune response to infection during acute (e.g., paracetamol ALF) and chronic (cirrhosis, MASLD) liver disease, that contribute to increased morbidity and mortality. Another significant area of interest within the lab is determining the mechanisms through which different checkpoint pathways e.g., PD-(L)1 and TIGIT, control peripheral and hepatic immune responses, at steady state and in liver inflammation, with the aim of exploiting this to produce new immune-directed therapies.